Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A severe form of congenital adrenal hyperplasia characterized by very low or absent activity of an enzyme in the steroidogenic pathway typically presenting early in life, and requiring life-long cortisol replacement.
Biomarker and diagnostic research for classic congenital adrenal hyperplasia has been reported in the published literature.
7 clinical trials registered, 4 recruiting. Interventions under study include drug therapy and biologic therapy. Pipeline includes 3 PHASE3, 3 PHASE2, 1 PHASE1. Research is primarily industry-sponsored.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07144163](https://clinicaltrials.gov/study/NCT07144163) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 4:33 PM UTC
Common questions about classic congenital adrenal hyperplasia
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
PHASE3 |
Crinetics Pharmaceuticals Inc. |
RECRUITING |
[NCT04490915](https://clinicaltrials.gov/study/NCT04490915) | Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia | PHASE3 | Neurocrine Biosciences | ACTIVE_NOT_RECRUITING |
[NCT07159841](https://clinicaltrials.gov/study/NCT07159841) | A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) | PHASE2 | Crinetics Pharmaceuticals Inc. | RECRUITING |
[NCT04783181](https://clinicaltrials.gov/study/NCT04783181) | A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) | PHASE1 | Adrenas Therapeutics Inc | ACTIVE_NOT_RECRUITING |
[NCT04806451](https://clinicaltrials.gov/study/NCT04806451) | Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) | PHASE3 | Neurocrine Biosciences | ACTIVE_NOT_RECRUITING |
75 publications have been identified in PubMed for classic congenital adrenal hyperplasia. Research spans Review / Meta-Analysis (27%), Epidemiology / Natural History (26%), and Case Report / Case Series (19%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 20 | 27% |
Disease patterns and progression | 19 | 26% |
Patient case studies | 14 | 19% |
Clinical study results | 9 | 12% |
Testing and diagnosis research | 7 | 9% |
Laboratory research | 5 | 7% |
Qiu R (2026). [PMID: 41594178](https://pubmed.ncbi.nlm.nih.gov/41594178/). *Diagnostics (Basel)*. [Case Report / Case Series]
Zhang Q (2026). [PMID: 41918383](https://pubmed.ncbi.nlm.nih.gov/41918383/). *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. [Case Report / Case Series]
Pinto J (2026). [PMID: 41212409](https://pubmed.ncbi.nlm.nih.gov/41212409/). *J Endocrinol Invest*. [Epidemiology / Natural History]
Hamidi O (2026). [PMID: 41921547](https://pubmed.ncbi.nlm.nih.gov/41921547/). *J Clin Endocrinol Metab*. [Clinical Trial Publication]
Mu J (2026). [PMID: 42108595](https://pubmed.ncbi.nlm.nih.gov/42108595/). *Clin Endocrinol (Oxf)*. [Review / Meta-Analysis]
de Hora MR (2026). [PMID: 40658805](https://pubmed.ncbi.nlm.nih.gov/40658805/). *J Clin Endocrinol Metab*. [Diagnostic / Biomarker]
Dayno AN (2026). [PMID: 41938119](https://pubmed.ncbi.nlm.nih.gov/41938119/). *Front Endocrinol (Lausanne)*. [Basic Science / Preclinical]
Yuan L (2026). [PMID: 41321281](https://pubmed.ncbi.nlm.nih.gov/41321281/). *Ann Pharmacother*. [Review / Meta-Analysis]
Nokoff NJ (2026). [PMID: 42082437](https://pubmed.ncbi.nlm.nih.gov/42082437/). *J Clin Endocrinol Metab*. [Clinical Trial Publication]
Tschaidse L (2026). [PMID: 41144104](https://pubmed.ncbi.nlm.nih.gov/41144104/). *J Endocrinol Invest*. [Clinical Trial Publication]